![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, November 21, 2020 10:25:41 PM
2020-11-17 07:00 ET - News Release
Mr. Greg Engel reports
ORGANIGRAM LAUNCHES EDISON RE:MIX RAPID DISSOLVABLE CANNABIS POWDER
Organigram Holdings Inc. has launched Edison Re:Mix dissolvable cannabis powder. Re:Mix is the latest innovation from the Company's Edison brand portfolio of products, offering Canadian adults the opportunity to enjoy cannabis their way.
Rapid dissolving and discreet formulations offer consumers highly customizable cannabis beverage experience;
Nanoemulsion formula offers improved absorption compared with traditional edibles;
Estimates suggest Canadian recreational cannabis beverage market represents $467-million category opportunity (i).
The convenient prepackaged powder format makes it easy to mix Edison Re:Mix into beverages quickly and discreetly, so the product can be enjoyed, based on the consumer's own preference, in a wide variety of settings and on occasions of their choosing.
"Edison Re:Mix showcases the creativity, focus and expertise of Organigram's product development team and reinforces our company commitment to growth through innovation," says Greg Engel, chief executive officer, Organigram. "We have developed a process and product that blend science and individual tastes to help adult Canadians explore new, personal cannabis experiences."
Key features of Edison Re:Mix include the following:
Customizable: Re:Mix can easily be added to almost any beverage, transforming it into a cannabis-infused drink in a matter of seconds (ii).
Rapid: Re:Mix dissolves rapidly into beverages for a quick, straightforward cannabis experience. In addition, the nanoemulsion formula provides improved absorption compared with traditional edibles, like a brownie or an ingestible oil.
Discreet: Re:Mix is odourless and mixes in clear to most drinks, making it a discreet addition. It also contains no added flavour.
The results of a recent Organigram survey suggest a significant majority of current cannabis consumers (74 per cent) would prefer to add cannabis to their beverages by themselves (versus a premixed beverage). The discreet nature of the product also addresses consumer concerns related to open cannabis consumption.
As previously announced, Organigram's researchers have developed a proprietary nano-emulsification technology that generates nano-droplets which are very small and uniform; this provides improved absorption compared with traditional solid edibles, potentially allowing for a more reliable and controlled experience.
With traditional edibles, beverages and ingestible oil-based extracts, the body spends significant time breaking down fat-soluble cannabinoid particles which are then absorbed and metabolized in the body before the effects are felt. This lengthy process can result in accidental overconsumption and undesirable experiences.
The nanoemulsion technology is also anticipated to have increased stability to temperature variations, mechanical disturbance, salinity, pH and sweeteners. The powdered formulation holds the potential to offer consumers a measured dose of cannabinoids which they can then add to liquid, such as a beverage of their choice, while also offering the discretion, portability and shelf life expected of a dried powder formulation.
Market opportunity
According to recent sales data in Colorado, cannabinoid-infused powders have rapidly risen to the top of the beverage category in popularity, representing 55 per cent of the state's beverage market sales. In fact, 46 per cent of cannabis consumers reported enjoying cannabinoid-infused beverages multiple times a day (iii).
In Canada, the recreational cannabis beverage market is expected to increase by 15 times its current market size over the next five years (iv).
Edison Re:Mix availability
Edison Re:Mix is available in three formats:
Two sachets with five milligrams of tetrahydrocannabinol per sachet;
Two sachets with 5:5 mg THC:CBD (cannabidiol) per sachet;
Five sachets with 10 mg CBD per sachet.
Edison Re:Mix will be available in certain provincial retail stores this month.
Recent LEXX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 04:25:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 03:32:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 03:12:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:12:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/12/2024 05:26:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/06/2024 11:00:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 07:28:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:59 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/16/2024 08:47:26 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:20:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 06:51:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 07:12:07 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/24/2024 06:33:08 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/18/2024 07:38:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 10:11:16 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs • InvestorsHub NewsWire • 01/08/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:07:45 PM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM